All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

N-of-1 Trials in Pediatric Oncology: From a Population-Based Approach to Personalized Medicine-A Review

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F21%3A00074836" target="_blank" >RIV/00159816:_____/21:00074836 - isvavai.cz</a>

  • Alternative codes found

    RIV/65269705:_____/21:00074836 RIV/00216224:14110/21:00123627

  • Result on the web

    <a href="https://www.mdpi.com/2072-6694/13/21/5428" target="_blank" >https://www.mdpi.com/2072-6694/13/21/5428</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.3390/cancers13215428" target="_blank" >10.3390/cancers13215428</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    N-of-1 Trials in Pediatric Oncology: From a Population-Based Approach to Personalized Medicine-A Review

  • Original language description

    Simple Summary: Clinical trials in pediatric oncology and personalized medicine are challenging due to the rarity of the disease, the low prevalence, and the ever-improving treatment outcomes. Many of the methods designed for small numbers and approaches used in classical population studies are not suitable for personalized pediatric oncology. There has been a change of perspective on the whole issue of rare diseases and personalized medicine. For example, a shift from a population to an individual perspective, generalizing from the individual to the population, using repeated measures and a within-subject design instead of parallel groups, exploring the variability instead of suppressing it, etc. N-of-1 should be understood as a whole range of approaches that fit the new inferential, evidential and analytical paradigms of modern medicine.&lt;/p&gt; Pediatric oncology is a critical area where the more efficient development of new treatments is urgently needed. The speed of approval of new drugs is still limited by regulatory requirements and a lack of innovative designs appropriate for trials in children. Childhood cancers meet the criteria of rare diseases. Personalized medicine brings it even closer to the horizon of individual cases. Thus, not all the traditional research tools, such as large-scale RCTs, are always suitable or even applicable, mainly due to limited sample sizes. Small samples and traditional versus subject-specific evidence are both distinctive issues in personalized pediatric oncology. Modern analytical approaches and adaptations of the paradigms of evidence are warranted. We have reviewed innovative trial designs and analytical methods developed for small populations, together with individualized approaches, given their applicability to pediatric oncology. We discuss traditional population-based and individualized perspectives of inferences and evidence, and explain the possibilities of using various methods in pediatric personalized oncology. We find that specific derivatives of the original N-of-1 trial design adapted for pediatric personalized oncology may represent an optimal analytical tool for this area of medicine. We conclude that no particular N-of-1 strategy can provide a solution. Rather, a whole range of approaches is needed to satisfy the new inferential and analytical paradigms of modern medicine. We reveal a new view of cancer as continuum model and discuss the &quot;evidence puzzle&quot;.&lt;/p&gt;

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30204 - Oncology

Result continuities

  • Project

    Result was created during the realization of more than one project. More information in the Projects tab.

  • Continuities

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2021

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Cancers

  • ISSN

    2072-6694

  • e-ISSN

  • Volume of the periodical

    13

  • Issue of the periodical within the volume

    21

  • Country of publishing house

    CH - SWITZERLAND

  • Number of pages

    18

  • Pages from-to

    5428

  • UT code for WoS article

    000718311900001

  • EID of the result in the Scopus database

    2-s2.0-85117926065